INR 16.9
(0.3%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -1.05 Billion INR | -27.25% |
2022 | -209.79 Million INR | -123.32% |
2021 | 269 Million INR | 222.13% |
2020 | -2.86 Billion INR | -118.84% |
2019 | 1.95 Billion INR | -48.86% |
2018 | 3.94 Billion INR | 27.22% |
2017 | 3.12 Billion INR | 19.85% |
2016 | 2.75 Billion INR | 22.47% |
2015 | 1.62 Billion INR | 38.15% |
2014 | 1.08 Billion INR | -2.2% |
2013 | 964.8 Million INR | -5.21% |
2012 | 1.61 Billion INR | 4.74% |
2011 | 1.45 Billion INR | 19.68% |
2010 | 1.09 Billion INR | 60.26% |
2009 | 714.57 Million INR | -12.71% |
2008 | 809.87 Million INR | 5.24% |
2007 | 874.58 Million INR | 70.19% |
2006 | 472.32 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 Q3 | 11.34 Million INR | -41.7% |
2023 Q4 | -152.18 Million INR | -1441.98% |
2023 FY | - INR | -27.25% |
2023 Q1 | -9.14 Million INR | -159.54% |
2023 Q2 | 19.45 Million INR | 312.8% |
2022 Q4 | 15.35 Million INR | 207.03% |
2022 FY | - INR | -123.32% |
2022 Q2 | -227.42 Million INR | -1468.28% |
2022 Q3 | -14.34 Million INR | 93.69% |
2022 Q1 | 16.62 Million INR | 105.74% |
2021 Q3 | -88.51 Million INR | -133.77% |
2021 Q4 | -289.36 Million INR | -226.92% |
2021 FY | - INR | 222.13% |
2021 Q2 | 262.1 Million INR | -20.99% |
2021 Q1 | 331.73 Million INR | -50.49% |
2020 Q2 | -765.1 Million INR | -79.54% |
2020 Q3 | 149.35 Million INR | 119.52% |
2020 Q4 | 670.05 Million INR | 348.64% |
2020 FY | - INR | -118.84% |
2020 Q1 | -426.13 Million INR | 71.29% |
2019 Q4 | -1.48 Billion INR | -232.8% |
2019 Q2 | 1.12 Billion INR | 1.92% |
2019 Q1 | 1.1 Billion INR | 46.49% |
2019 FY | - INR | -48.86% |
2019 Q3 | 1.11 Billion INR | -0.65% |
2018 Q1 | 1.01 Billion INR | 8.93% |
2018 Q3 | 909.2 Million INR | -23.31% |
2018 Q4 | 753.46 Million INR | -17.13% |
2018 FY | - INR | 27.22% |
2018 Q2 | 1.18 Billion INR | 16.56% |
2017 Q4 | 933.8 Million INR | 15.03% |
2017 FY | - INR | 19.85% |
2017 Q3 | 811.77 Million INR | 14.23% |
2017 Q2 | 710.61 Million INR | 5.64% |
2017 Q1 | 672.66 Million INR | 5.36% |
2016 FY | - INR | 22.47% |
2016 Q1 | 629.13 Million INR | -3.33% |
2016 Q2 | 693.78 Million INR | 10.28% |
2016 Q3 | 667.69 Million INR | -3.76% |
2016 Q4 | 638.46 Million INR | -4.38% |
2015 Q4 | 650.83 Million INR | 27.46% |
2015 FY | - INR | 38.15% |
2015 Q3 | 510.6 Million INR | -0.39% |
2015 Q2 | 512.6 Million INR | -23.07% |
2015 Q1 | 666.35 Million INR | 59.25% |
2014 Q2 | 346.71 Million INR | 5.58% |
2014 Q1 | 328.4 Million INR | -10.12% |
2014 FY | - INR | -2.2% |
2014 Q4 | 418.42 Million INR | 3.88% |
2014 Q3 | 402.78 Million INR | 16.17% |
2013 Q1 | 368.07 Million INR | 21.34% |
2013 Q2 | 396.18 Million INR | 7.64% |
2013 Q3 | 400.4 Million INR | 1.07% |
2013 FY | - INR | -5.21% |
2013 Q4 | 365.37 Million INR | -8.75% |
2012 Q1 | 483.84 Million INR | 29.36% |
2012 Q2 | 429.63 Million INR | -11.2% |
2012 FY | - INR | 4.74% |
2012 Q4 | 303.35 Million INR | -23.64% |
2012 Q3 | 397.23 Million INR | -7.54% |
2011 Q3 | 421.54 Million INR | 9.59% |
2011 FY | - INR | 19.68% |
2011 Q2 | 384.67 Million INR | 0.0% |
2011 Q4 | 374.02 Million INR | -11.27% |
2010 FY | - INR | 60.26% |
2009 FY | - INR | -12.71% |
2008 FY | - INR | 5.24% |
2007 FY | - INR | 70.19% |
2006 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Biocon Limited | 41.52 Billion INR | 102.531% |
Blue Jet Healthcare Limited | 2.29 Billion INR | 145.842% |
Concord Biotech Limited | 4.65 Billion INR | 122.555% |
Dishman Carbogen Amcis Limited | 3.07 Billion INR | 134.209% |
Jubilant Ingrevia Limited | 4.56 Billion INR | 123.023% |
Lyka Labs Limited | 167.58 Million INR | 727.034% |
Panacea Biotec Limited | -47.58 Million INR | -2108.575% |
Piramal Pharma Limited | 13.05 Billion INR | 108.049% |
SMS Lifesciences India Limited | 349.41 Million INR | 400.747% |
Supriya Lifescience Limited | 1.83 Billion INR | 157.243% |
Syngene International Limited | 10.84 Billion INR | 109.688% |
Zota Health Care Limited | 82.07 Million INR | 1380.372% |